MEDP

In a comparison of two Medical Services stocks, Concentra Group (CON) emerges as the superior value option compared to Medpace (MEDP). CON holds a Zacks Rank of #2 (Buy) with improving earnings outlook and more attractive valuation metrics, including a forward P/E of 22.74 versus MEDP's 34.77, and a PEG ratio of 1.37 versus 2.72. CON also received a Value grade of B compared to MEDP's D grade.

Medpace (MEDP) closed down 1.64% and currently holds a Zacks Rank #3 (Hold) rating. The stock trades at a Forward P/E of 35.35, significantly above the industry average of 17.86, and a PEG ratio of 2.77 versus the industry average of 1.67. While earnings are expected to grow 15.28% next quarter and 14.79% for the full year, the premium valuation suggests limited upside potential in the near term.

Medpace stock declined 2.84% on October 6, 2026, underperforming the broader market gains. The company is expected to report earnings on October 21 with projected EPS of $4.45 (up 15.28% YoY) and revenue of $708.75 million (up 7.4% YoY). However, the stock trades at a premium valuation with a Forward P/E of 35.38 versus the industry average of 16.59, and holds a Zacks Rank of #3 (Hold).